Our Pipeline
We are harnessing the power of data and machine learning to program biology to dramatically improve the human condition in areas such as oncology, immunology, and infectious disease.
Program | Target | Generating | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Collaborations |
---|---|---|---|---|---|---|---|
Immunology | |||||||
GB-0895 | TSLP | ||||||
Generation program | TL1A | ||||||
Generation program | IL-13 | ||||||
Infectious Disease | |||||||
GB-0669 | SARS-CoV-2 S2 Domain |
||||||
SARS | SARS-CoV-2 RBD Domain |
||||||
Influenza | |||||||
Oncology | |||||||
Generation program | The University of Texas MD Anderson Cancer Center |
||||||
Generation program | The University of Texas MD Anderson Cancer Center |
||||||
Generation program | |||||||
Generation program | |||||||
Generation program | ![]() |
||||||
Generation program | ![]() |
||||||
Metabolic | |||||||
Generation program | |||||||
Undisclosed | |||||||
Generation program | Undisclosed | ![]() |
|||||
Generation program | Undisclosed | ![]() |
|||||
Generation program | Undisclosed | ![]() |
|||||
Generation program | Undisclosed | ![]() |
|||||
Generation program | Undisclosed | ![]() |
Policy on Expanded Access (EA) to Investigational Drugs
Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.